Personal information

No personal information available

Activities

Collapse all

Employment (1)

Fred Hutchinson Cancer Research Center: Seattle, WA, US

Employment
Source: check_circle
Fred Hutchinson Cancer Center

Education and qualifications (4)

Fred Hutchinson/University of Washington Cancer Consortium: Seattle, Washington, US

2008 | Fellowship (Medical Oncology)
Education
Source: Self-asserted source
Brian Till

Hospital of the University of Pennsylvania: Philadelphia, Pennsylvania, US

2005 | Residency (Internal Medicine)
Education
Source: Self-asserted source
Brian Till

University of Chicago: Chicago, US

2002 | M.D.
Education
Source: Self-asserted source
Brian Till

Catholic University of America: Washington D.C., District of Columbia, US

1998 | B.S.
Education
Source: Self-asserted source
Brian Till

Works (50 of 71)

Items per page:
Page 1 of 2

Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma.

Blood
2023-05-01 | Journal article
DOI: 10.1182/blood.2022019254
PMID: 36913694
Contributors: Ryan C Lynch; Ujjani CS; Poh C; Edus Warren; Stephen Smith; Mazyar Shadman; Till B; Raghunathan VM; Stefan Karl Christian Alig; Ash A. Alizadeh, MD/PhD et al.
Source: Self-asserted source
Brian Till

Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world study.

Journal of cellular and molecular medicine
2022-12-01 | Journal article
DOI: 10.1111/jcmm.17550
PMID: 36453136
PMC: PMC9753434
Contributors: Lorenzo Iovino; Wu QV; Voutsinas J; Panaite L; Mullane E; Ryan C Lynch; Chaitra Ujjani; Stephen Smith; Gopal AK; Till BG et al.
Source: Self-asserted source
Brian Till

Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients.

Cancer immunology, immunotherapy : CII
2022-08-05 | Journal article
DOI: 10.1007/s00262-022-03259-5
PMID: 35931835
Contributors: Yuan S; Peng L; Liu Y; Till BG; Yan X; Zhang J; Zhu L; Wang H; Zhang S; hongle Li et al.
Source: Self-asserted source
Brian Till

Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy.

Cancer immunology, immunotherapy : CII
2022-07-30 | Journal article
DOI: 10.1007/s00262-022-03254-w
PMID: 35907016
Contributors: An M; Wang W; Zhang J; Till BG; Zhao L; Huang H; Yang Y; Li T; Han L; Zhang X et al.
Source: Self-asserted source
Brian Till

Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced Malignancies.

Frontiers in immunology
2022-07-13 | Journal article
DOI: 10.3389/fimmu.2022.882172
PMID: 35911715
PMC: PMC9328170
Contributors: Huang H; Peng L; Zhang B; Till BG; Yang Y; Zhang X; Zhao L; Fu X; Li T; Han L et al.
Source: Self-asserted source
Brian Till

Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma.

Leukemia & lymphoma
2022-07-09 | Journal article
DOI: 10.1080/10428194.2022.2095632
PMID: 35811554
Contributors: Panaite L; Wu QV; Voutsinas J; Mullane E; Chow VA; Lynch RC; Ujjani CS; Smith SD; Gopal AK; Poh C et al.
Source: Self-asserted source
Brian Till

The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia.

British journal of haematology
2022-02-18 | Journal article
DOI: 10.1111/bjh.18088
PMID: 35149986
PMC: PMC9111753
Contributors: Ujjani C; Shadman M; Lynch RC; Tu B; Stevenson PA; Grainger C; Zhu H; Hill JA; Huang ML; Nielsen L et al.
Source: Self-asserted source
Brian Till

Role of fibrosarcoma-induced CD11b<sup>+</sup> myeloid cells and tumor necrosis factor-α in B cell responses.

Oncogene
2022-01-15 | Journal article
DOI: 10.1038/s41388-022-02187-z
PMID: 35034094
Contributors: Zibing; Liu Y; Ling Peng; Till B; Liao Y; Yuan S; Xiang Yan; Chen L; Fu Q; Zhihai Qin
Source: Self-asserted source
Brian Till

Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study.

Clinical lymphoma, myeloma & leukemia
2021-12-24 | Journal article
DOI: 10.1016/j.clml.2021.12.010
PMID: 35031227
Contributors: Palomba ML; Till BG; Park SI; Morschhauser F; Cartron G; Marks R; Shivhare M; Wan-Jen Hong; Raval A; Chang AC et al.
Source: Self-asserted source
Brian Till
grade
Preferred source (of 2)‎

Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma.

Frontiers in oncology
2021-10-29 | Journal article
DOI: 10.3389/fonc.2021.728253
PMID: 34778042
PMC: PMC8586206
Contributors: Yang Y; Li J; Till BG; Wang J; Zhang B; Wang H; Huang H; Li T; Gao Q; Li H et al.
Source: Self-asserted source
Brian Till

Scalable Manufacturing of CAR T cells for Cancer Immunotherapy.

Blood cancer discovery
2021-08-03 | Journal article
DOI: 10.1158/2643-3230.bcd-21-0084
PMID: 34568831
PMC: PMC8462122
Contributors: Mohamed Abou-el-Enein; Magdi Elsallab; Steven A. Feldman; Andrew Fesnak; Helen Heslop; Marks P; Till BG; Bauer G; Savoldo B
Source: Self-asserted source
Brian Till

Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.

The Lancet. Haematology
2021-08-01 | Journal article
DOI: 10.1016/s2352-3026(21)00170-8
PMID: 34329577
PMC: PMC8457616
Contributors: Lynch RC; Cassaday RD; Smith SD; Fromm JR; Cowan AJ; Edus Warren; Shadman MS; Shustov A; Till BG; Ujjani CS et al.
Source: Self-asserted source
Brian Till

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.

Blood
2021-01-01 | Journal article
DOI: 10.1182/blood.2020006770
PMID: 32967009
PMC: PMC7819764
Contributors: Gauthier J; Bezerra ED; Hirayama AV; Salvatore Fiorenza; Sheih A; Chou CK; Erik Kimble; Pender BS; Hawkins RM; Vakil A et al.
Source: Self-asserted source
Brian Till

Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and <sup>90</sup>Y-DOTA.

Molecular cancer therapeutics
2020-10-20 | Journal article
DOI: 10.1158/1535-7163.mct-20-0306
PMID: 33082277
PMC: PMC7718432
Contributors: Orozco JJ; Kenoyer AL; Lin Y; Shyril O'Steen; Guel R; Nartea ME; Hernandez AH; Hylarides MD; Fisher DR; Ethan R. Balkin et al.
Source: Self-asserted source
Brian Till

Pretreatment Peripheral B Cells Are Associated With Tumor Response to Anti-PD-1-Based Immunotherapy.

Frontiers in immunology
2020-10-09 | Journal article
DOI: 10.3389/fimmu.2020.563653
PMID: 33162976
PMC: PMC7584071
Contributors: Yuan S; Liu Y; Till B; Song Y; Wang Z
Source: Self-asserted source
Brian Till

Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma.

Transplantation and cellular therapy
2020-09-25 | Journal article
DOI: 10.1016/j.bbmt.2020.09.021
PMID: 32980545
PMC: PMC7990745
Contributors: Tuazon SA; Cassaday RD; Gooley TA; Sandmaier BM; Holmberg LA; Smith SD; Maloney DG; Till BG; Martin DB; Chow VA et al.
Source: Self-asserted source
Brian Till

<sup>90</sup>Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma.

Bone marrow transplantation
2020-07-24 | Journal article | Author
DOI: 10.1038/s41409-020-01000-3
PMID: 32710011
PMC: PMC8328580
Contributors: Sherilyn Tuazon; Sandmaier BM; Gooley TA; Fisher DR; Holmberg LA; Pamela Becker; Lundberg SJ; Orozco JJ; Gopal AK; Brian Till et al.
Source: Self-asserted source
Brian Till
grade
Preferred source (of 2)‎

Addressing the conundrum of male predominance in mantle cell lymphoma using androgen receptor blockade.

British journal of haematology
2020-06-22 | Journal article
DOI: 10.1111/bjh.16902
PMID: 32567674
Contributors: Victor Chow; Martin PS; Smith SD; Till BG; Graf SA; Edlefsen KL; Hannan LM; Mostaghel EA; Ajay Gopal
Source: Self-asserted source
Brian Till

Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy.

British journal of haematology
2020-02-06 | Journal article
DOI: 10.1111/bjh.16494
PMID: 32030732
Contributors: Stephen Smith; Till BG; Shadman MS; Lynch RC; Cowan AJ; Qian (Vicky) Wu; Voutsinas J; Rasmussen HA; Blue K; Chaitra Ujjani et al.
Source: Self-asserted source
Brian Till

Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.

Practical radiation oncology
2019-10-01 | Journal article
DOI: 10.1016/j.prro.2019.09.013
PMID: 31585205
Contributors: Kim A; Stevenson P; Cassaday RD; Soma L; Fromm JR; Gopal AK; Smith SD; Till B; Lynch RC; Ujjani C et al.
Source: Self-asserted source
Brian Till

Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy.

Blood advances
2019-10-01 | Journal article
DOI: 10.1182/bloodadvances.2019000593
PMID: 31648329
PMC: PMC6849954
Contributors: Shadman M; Gauthier J; Kevin Hay; Voutsinas JM; Milano F; Ang Li; Hirayama AV; Sorror ML; Cherian S; Chen X et al.
Source: Self-asserted source
Brian Till

Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.

American journal of hematology
2019-05-21 | Journal article
DOI: 10.1002/ajh.25505
PMID: 31056762
PMC: PMC6776079
Contributors: Victor Chow; Ajay Gopal; Maloney DG; Turtle CJ; Stephen Smith; Ujjani CS; Shadman M; Cassaday RD; Till BG; Tseng YD et al.
Source: Self-asserted source
Brian Till

Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States.

British journal of haematology
2019-05-01 | Journal article
DOI: 10.1111/bjh.15923
PMID: 31044423
PMC: PMC8989046
Contributors: Geer M; Emily Roberts; Shango M; Till BG; Smith SD; Abbas H; Brian Hill; Kaplan J; Barr PM; Caimi P et al.
Source: Self-asserted source
Brian Till

Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience.

Clinical lymphoma, myeloma & leukemia
2019-03-11 | Journal article
DOI: 10.1016/j.clml.2019.03.003
PMID: 30948330
Contributors: Jason P Cooper; Khajaviyan S; Smith SD; Maloney DG; Shustov AR; Edus Warren; Soma LA; Lynch RC; Ujjani C; Till B et al.
Source: Self-asserted source
Brian Till

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.

Blood
2019-02-19 | Journal article | Author
DOI: 10.1182/blood-2018-11-887067
PMID: 30782611
PMC: PMC6484391
Contributors: Alexandre Vinaud Hirayama; Jordan Gauthier; Kevin Hay; Voutsinas JM; Wu Q; Gooley T; Li D; Cherian S; Chen X; Pender BS et al.
Source: Self-asserted source
Brian Till

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.

Blood
2019-02-06 | Journal article | Author
DOI: 10.1182/blood-2018-11-883710
PMID: 30728140
PMC: PMC6460418
Contributors: Kevin Hay; Jordan Gauthier; Alexandre Vinaud Hirayama; Voutsinas JM; Qian (Vicky) Wu; Li D; Ted Gooley; Cherian S; Chen X; Pender BS et al.
Source: Self-asserted source
Brian Till

Eligibility for CAR T-cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCL.

American journal of hematology
2019-02-04 | Journal article
DOI: 10.1002/ajh.25411
PMID: 30663774
Contributors: Stephen Smith; Reddy P; Sokolova A; Chow VA; Lynch RC; Shadman MA; Till BG; Shustov AR; Warren EH; Ujjani CS et al.
Source: Self-asserted source
Brian Till

Construction and functional characterization of a fully human anti-CD19 chimeric antigen receptor (huCAR)-expressing primary human T cells.

Journal of cellular physiology
2018-10-26 | Journal article
DOI: 10.1002/jcp.27599
PMID: 30362586
Contributors: Hamid Reza Mirzaei; Jamali A; Jafarzadeh L; Elham Masoumi; Alishah K; Keyvan Fallah-mehrjardi; Emami SAH; Noorbakhsh F; Till BG; Jamshid Hadjati
Source: Self-asserted source
Brian Till

Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma.

Clinical lymphoma, myeloma & leukemia
2018-10-17 | Journal article
DOI: 10.1016/j.clml.2018.10.006
PMID: 30409719
Contributors: Smith SD; Gandhy S; Gopal AK; Reddy P; Shadman M; Till BG; Lynch RC; Kanan S; Cowan A; Low L et al.
Source: Self-asserted source
Brian Till

Predictive and therapeutic biomarkers in chimeric antigen receptor T-cell therapy: A clinical perspective.

Journal of cellular physiology
2018-10-14 | Journal article
DOI: 10.1002/jcp.27519
PMID: 30317583
Contributors: Hamid Reza Mirzaei; hamed mirzaei; Namdar A; Majid Rahmati; Till BG; Jamshid Hadjati
Source: Self-asserted source
Brian Till

Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma.

Blood research
2018-09-28 | Journal article
DOI: 10.5045/br.2018.53.3.223
PMID: 30310789
PMC: PMC6170297
Contributors: Greenbaum AM; Green DJ; Holmberg LA; Gooley T; Till BG; Budde LE; Rasmussen H; Press OW; Gopal AK
Source: Self-asserted source
Brian Till

Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma.

Current treatment options in oncology
2018-07-21 | Journal article
DOI: 10.1007/s11864-018-0561-x
PMID: 30032463
Contributors: Till BG
Source: Self-asserted source
Brian Till

Combination of Cytokine-Induced Killer Cells and Programmed Cell Death-1 Blockade Works Synergistically to Enhance Therapeutic Efficacy in Metastatic Renal Cell Carcinoma and Non-Small Cell Lung Cancer.

Frontiers in immunology
2018-07-05 | Journal article
DOI: 10.3389/fimmu.2018.01513
PMID: 30026742
PMC: PMC6041387
Contributors: Wang Z; Liu X; Till B; Sun M; Li X; Gao Q
Source: Self-asserted source
Brian Till

Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions.

Journal of immunotherapy (Hagerstown, Md. : 1997)
2018-01-01 | Journal article
DOI: 10.1097/cji.0000000000000199
PMID: 29176334
PMC: PMC5759780
Contributors: Lee SY; Olsen P; Lee DH; Kenoyer AL; Budde LE; O'Steen S; Green DJ; Heimfeld S; Jensen MC; Riddell SR et al.
Source: Self-asserted source
Brian Till

CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.

Blood
2017-11-20 | Journal article | Author
DOI: 10.1182/blood-2017-09-807610
PMID: 29158362
PMC: PMC5805491
Contributors: Damian Green; Shyril O'Steen; Yukang Lin; Comstock ML; Kenoyer AL; Hamlin DK; Wilbur DS; Darrell Fisher; Nartea M; Mark Hylarides et al.
Source: Self-asserted source
Brian Till

Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
2017-10-20 | Journal article
DOI: 10.1016/j.bbmt.2017.10.029
PMID: 29061536
Contributors: Tseng YD; Stevenson PA; Cassaday RD; Cowan A; Till BG; Shadman M; Graf SA; Ermoian R; Smith SD; Holmberg LA et al.
Source: Self-asserted source
Brian Till
grade
Preferred source (of 2)‎

Pegylated GCSF Can Be Used With First-Line da-EPOCH-R Without Compromising Dose Intensity, Safety, or Efficacy.

Clinical lymphoma, myeloma & leukemia
2017-08-14 | Journal article
DOI: 10.1016/j.clml.2017.08.098
PMID: 28870643
Contributors: Reddy P; Kanan S; Cowan A; Edus Warren; Till B; Shadman M; Cassaday R; Oliver W. Press; Shustov A; Ajay Gopal et al.
Source: Self-asserted source
Brian Till

Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells.

Oncoimmunology
2017-06-16 | Journal article
DOI: 10.1080/2162402x.2017.1331807
PMID: 28811975
PMC: PMC5543863
Contributors: Wang Z; Till B; Gao Q
Source: Self-asserted source
Brian Till

Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.

Cancer research
2017-05-31 | Journal article
DOI: 10.1158/0008-5472.can-17-0082
PMID: 28566329
PMC: PMC5560265
Contributors: O'Steen S; Green DJ; Ajay Gopal; Orozco JJ; Kenoyer AL; Lin Y; Wilbur DS; Hamlin DK; Fisher DR; Hylarides MD et al.
Source: Self-asserted source
Brian Till

Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.

Journal of the National Cancer Institute
2016-12-31 | Journal article
DOI: 10.1093/jnci/djw263
PMID: 28040733
PMC: PMC6059122
Contributors: Spurgeon SE; Till BG; Martin P; Goy AH; Dreyling MP; Ajay Gopal; LeBlanc M; Leonard JP; Friedberg JW; Baizer L et al.
Source: Self-asserted source
Brian Till

Minimal detectable disease confirmed by flow cytometry and poor outcome after autologous stem cell transplantation in peripheral T-Cell lymphomas.

Bone marrow transplantation
2016-10-24 | Journal article
DOI: 10.1038/bmt.2016.227
PMID: 27775693
Contributors: Jordan Gauthier; Holmberg L; Wu D; Bensinger W; Ajay Gopal; Oliver W. Press; Maloney D; Green DJ; Till BG; Byelykh D et al.
Source: Self-asserted source
Brian Till

Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers.

Cancer research
2016-09-02 | Journal article
DOI: 10.1158/0008-5472.can-16-0571
PMID: 27590740
PMC: PMC5290195
Contributors: Green DJ; Frayo SL; Lin Y; Hamlin DK; Fisher DR; Frost SH; Kenoyer AL; Hylarides MD; Ajay Gopal; Gooley TA et al.
Source: Self-asserted source
Brian Till

Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.

Cancer letters
2016-07-05 | Journal article
DOI: 10.1016/j.canlet.2016.07.001
PMID: 27392648
PMC: PMC5003697
Contributors: Mirzaei HR; Mirzaei H; Lee SY; Jamshid Hadjati; Till BG
Source: Self-asserted source
Brian Till

Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma.

Bone marrow transplantation
2016-05-23 | Journal article
DOI: 10.1038/bmt.2016.123
PMID: 27214069
PMC: PMC5052091
Contributors: Green DJ; Bensinger WI; Holmberg LA; Gooley T; Till BG; Budde LE; Pagel JM; Frayo SL; Roden JE; Hedin L et al.
Source: Self-asserted source
Brian Till

Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.

Cancer immunology research
2016-04-21 | Journal article
DOI: 10.1158/2326-6066.cir-15-0276
PMID: 27197068
PMC: PMC4891234
Contributors: Rufener GA; Oliver W. Press; Olsen P; Lee SY; Jensen MC; Ajay Gopal; Pender B; Budde LE; Rossow JK; Green DJ et al.
Source: Self-asserted source
Brian Till

Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.

British journal of haematology
2015-10-22 | Journal article
DOI: 10.1111/bjh.13818
PMID: 26492567
PMC: PMC4710555
Contributors: Till BG; Li H; Bernstein SH; Fisher RI; Burack WR; Rimsza LM; Floyd JD; DaSilva MA; Moore DF Jr; Pozdnyakova O et al.
Source: Self-asserted source
Brian Till

High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma.

British journal of haematology
2015-10-12 | Journal article
DOI: 10.1111/bjh.13773
PMID: 26455717
PMC: PMC4715476
Contributors: Cassaday RD; Stevenson PA; Gooley TA; Chauncey TR; Pagel JM; Rajendran J; Till BG; Philip M; Orozco JJ; Bensinger WI et al.
Source: Self-asserted source
Brian Till

Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology
2015-09-07 | Journal article
DOI: 10.1093/annonc/mdv364
PMID: 26347113
PMC: PMC4621031
Contributors: Graf SA; Stevenson PA; Holmberg LA; Till BG; Oliver W. Press; Chauncey TR; Smith SD; Philip M; Orozco JJ; Shustov AR et al.
Source: Self-asserted source
Brian Till

Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
2015-09-05 | Journal article
DOI: 10.1016/j.bbmt.2015.08.035
PMID: 26348890
PMC: PMC4716882
Contributors: Cowan AJ; Stevenson PA; Cassaday RD; Graf SA; Fromm JR; Wu D; Holmberg LA; Till BG; Chauncey TR; Smith SD et al.
Source: Self-asserted source
Brian Till

Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.

Blood
2015-01-27 | Journal article | Author
DOI: 10.1182/blood-2014-11-612770
PMID: 25628467
PMC: PMC4375108
Contributors: Damian Green; Mazyar Shadman; Jones JC; Frayo SL; Kenoyer AL; Mark Hylarides; Hamlin DK; Wilbur DS; Ethan R. Balkin; Yukang Lin et al.
Source: Self-asserted source
Brian Till
Items per page:
Page 1 of 2
How many people are using ORCID?